Back

Underuse of hepatocellular carcinoma surveillance in patients with cirrhosis: a nested cohort study.

Caillet, P.; Balusson, F.; Ganne, N.; Oger, E.; Costentin, C.; Ganry, O.

2025-09-18 gastroenterology
10.1101/2025.09.16.25335849 medRxiv
Show abstract

ObjectivesHepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Most cases occur in patients with an underlying cirrhosis. The French national guidelines recommend semiannual abdominal ultrasound surveillance for early HCC detection in patients with cirrhosis. The primary goal of our retrospective cohort study was to evaluate compliance with this recommendation. MethodsWe used 2007-2016 general public health insurance program (Regime General) data from the French National Health Data System (Systeme National des Donnees de Sante, or SNDS). Included patients were 18 to 75 years old, diagnosed with liver cirrhosis between 2009 and 2013, and underwent their first ultrasound >4 months after their index date. The number of annual ultrasounds was recorded over a 3-year follow-up period. Compliance was defined as having had at least 2 ultrasounds per year over the follow-up time. ResultsAmong the 66,464 patients included in the analysis, surveillance was optimal (no year with <2 ultrasounds) in 5,082 patients (7.6%), suboptimal (one year with <2 ultrasounds) in 3,928 (5.9%), and failed (remaining cases) in 57,454 (86.4%). Older age, male sex, a high Charlson index, frequent gastroenterologist/hepatologist visits, and viral etiology were associated with better surveillance, whereas low socioeconomic status, despite Frances universal health coverage, was linked to failed surveillance. ConclusionsIn French patients with cirrhosis, most of cancer surveillance is failing when considering recommendation in vigor. In order to improve surveillance, a better understanding of the social determinants of health equity is needed.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Hepatology
18 papers in training set
Top 0.1%
18.6%
2
Gut
36 papers in training set
Top 0.1%
14.6%
3
Hepatology Communications
21 papers in training set
Top 0.1%
12.3%
4
Gastroenterology
40 papers in training set
Top 0.2%
9.1%
50% of probability mass above
5
International Journal of Cancer
42 papers in training set
Top 0.1%
6.3%
6
BMC Medicine
163 papers in training set
Top 1%
3.6%
7
PLOS ONE
4510 papers in training set
Top 40%
3.6%
8
American Journal of Gastroenterology
15 papers in training set
Top 0.1%
3.6%
9
Frontiers in Medicine
113 papers in training set
Top 2%
3.0%
10
British Journal of Cancer
42 papers in training set
Top 0.7%
2.1%
11
Journal of Clinical Medicine
91 papers in training set
Top 2%
2.1%
12
BMJ Open
554 papers in training set
Top 9%
1.7%
13
Cancers
200 papers in training set
Top 3%
1.5%
14
Communications Medicine
85 papers in training set
Top 0.4%
1.3%
15
Frontiers in Oncology
95 papers in training set
Top 3%
1.2%
16
Nature Communications
4913 papers in training set
Top 56%
1.2%
17
Journal of Translational Medicine
46 papers in training set
Top 2%
1.1%
18
Scientific Reports
3102 papers in training set
Top 68%
1.1%
19
Journal of Hepatology
18 papers in training set
Top 0.3%
0.9%
20
The Lancet Global Health
24 papers in training set
Top 0.9%
0.9%
21
Clinical and Translational Science
21 papers in training set
Top 0.8%
0.9%
22
Open Forum Infectious Diseases
134 papers in training set
Top 2%
0.8%
23
International Journal of Infectious Diseases
126 papers in training set
Top 3%
0.8%
24
American Journal of Physiology-Gastrointestinal and Liver Physiology
11 papers in training set
Top 0.3%
0.6%